Korean Circ J.  1988 Dec;18(4):605-612. 10.4070/kcj.1988.18.4.605.

The Difference of the Rate of Regression of the left Ventricular Mass between the Age Groups in the Hypertensive Patients with the Left Ventricular Hypertrophy with the Control of Blood Pressure by Angiotensin Converting Enzyme Inhibitor

Abstract

The left ventricular hypertrophy(LVH) in the hypertensive patients is known to be associated with relatively higher risk for cardiovascular morbidity and mortality. In this sense the reversal of LVH with blood pressure control, if attained, could yeild an additional benefit of reducing cardiovascular morbidity and/or mortaility associated with hypertension. However pathogenesis of LVH, the attitude of the LVH to regerss with blood pressure control in a particular patient and whether the regression is really beneficial are not clear. In order to see the effect of angiotensin converting enzyme(ACE) inhibitors on LVH and the age group difference of the LVH regresion, if attainable, 26 hypertensive patients with LVH(LVMI:Left Ventricular Mass Index>125g/m2) were treated with enalapril or captopril for more than 12 weeks and the LVMI followed and the regression rates in younger group "A"(less than 50 years of age) and elder group "B" were compared(LVMI, level of blood pressure, kinds and dosage of enalapril or captopril were not different between the two groups). The LVMI was significantly decreased in both groups, in group A from 191.6+/-74.9g/m2 to 139.7+/-52.0g/m2, and in group B from 185.5+/-58.7g/m2 to 163.9+/-58.7g/m2. In group A the percent decrease of LVMI was significantly higher than that of group B(25.3+/-14.9% versus 10.3+/-8.6%, p<0.005). Above results suggest that enalapril and captopril are equally effective in reducing LVMI in hypertensive patients with LVH and the regression of the LVMI is more marked in the younger age group in this relatively short-term treated small population study.

Keyword

LVM regression; Antiyhpertensive treatment; ACE inhibitors

MeSH Terms

Angiotensin-Converting Enzyme Inhibitors
Angiotensins*
Blood Pressure*
Captopril
Enalapril
Humans
Hypertension
Hypertrophy, Left Ventricular*
Mortality
Peptidyl-Dipeptidase A*
Angiotensin-Converting Enzyme Inhibitors
Angiotensins
Captopril
Enalapril
Peptidyl-Dipeptidase A
Full Text Links
  • KCJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr